Read More

EXCLUSIVE: Data Monitoring Committee Allows BioRestorative’s Chronic Lumbar Disc Disease To Continue Unchanged

BioRestorative Therapies Inc (NASDAQ: BRTX) has announced that the independent Data Safety Monitoring Board (DSMB), overseeing the company's ongoing Phase 2 trial to treat chronic lumbar disc disease, unanimously recommended the continuation of the study under the current version of the protocol wi

BRTX

Read More

EXCLUSIVE: SciSparc’s Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US

SciSparc Ltd (NASDAQ: SPRC) has received Institutional Review Board (IRB) approval for its Phase 2b clinical trial for SCI-110 in subjects suffering from Tourette Syndrome. Tourette Syndrome is a nervous system condition in which people have "tics." 

SPRC